PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
Looking for a particular PEP-Therapy employee's phone or email?
PEP-Therapy Questions
The PEP-Therapy annual revenue was $1 million in 2026.
Antoine Prestat is the Co-founder and CEO of PEP-Therapy.
7 people are employed at PEP-Therapy.
PEP-Therapy is based in Paris, Île-de-France.
The NAICS codes for PEP-Therapy are [541, 54171, 5417, 54, 541713].
The SIC codes for PEP-Therapy are [87, 873].
Top PEP-Therapy Employees
-
Antoine Prestat
Co-founder and CEO at PEP-Therapy
Île-de-France, France22 -
2
-
Piedad Dickinson
Designer at PEP-Therapy
New York, United States1
Related Companies
